SNGX vs. ADIL, HOTH, SNPX, KA, XBIO, ENSC, LIXT, AIMD, BFRI, and LIPO
Should you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Adial Pharmaceuticals (ADIL), Hoth Therapeutics (HOTH), Synaptogenix (SNPX), Kineta (KA), Xenetic Biosciences (XBIO), Ensysce Biosciences (ENSC), Lixte Biotechnology (LIXT), Ainos (AIMD), Biofrontera (BFRI), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "pharmaceutical preparations" industry.
Adial Pharmaceuticals (NASDAQ:ADIL) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.
Soligenix has a consensus price target of $3.00, indicating a potential upside of 733.33%. Given Adial Pharmaceuticals' higher possible upside, analysts clearly believe Soligenix is more favorable than Adial Pharmaceuticals.
Adial Pharmaceuticals has a net margin of 0.00% compared to Adial Pharmaceuticals' net margin of -1,025.66%. Soligenix's return on equity of -170.85% beat Adial Pharmaceuticals' return on equity.
In the previous week, Soligenix had 4 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 6 mentions for Soligenix and 2 mentions for Adial Pharmaceuticals. Soligenix's average media sentiment score of 1.02 beat Adial Pharmaceuticals' score of 0.41 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.
Soligenix received 170 more outperform votes than Adial Pharmaceuticals when rated by MarketBeat users. Likewise, 72.97% of users gave Soligenix an outperform vote while only 58.06% of users gave Adial Pharmaceuticals an outperform vote.
16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 14.5% of Adial Pharmaceuticals shares are owned by insiders. Comparatively, 1.4% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Adial Pharmaceuticals has higher earnings, but lower revenue than Soligenix.
Adial Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500.
Summary
Soligenix beats Adial Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Soligenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soligenix Competitors List
Related Companies and Tools
